All 1 tracked stories fall under one category: market-trends. Verbund is most often covered alongside Dinesh Patel, which appears in 1 of these 1 story. The 5 average consequence score is below the beat benchmark of 6.3 in the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Verbund
All 1 tracked stories fall under one category: market-trends. Verbund is most often covered alongside Dinesh Patel, which appears in 1 of these 1 story. The 5 average consequence score is below the beat benchmark of 6.3 in the same window. Each story carries 2 original sources on average, compared with 3.1 for the broader beat in this window. Verbund appears in 1 tracked Healthcare story from March 17, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 34 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Verbund. Shared-story counts are live from our verified record — not editorial picks.
Protagonist Therapeutics (PTGX) is scheduled to release its quarterly earnings on Wednesday, March 18, 2026, with investors focused on the commercialization path for rusfertide and the Phase 3 progress of its oral IL-23 receptor antagonist, icotrokinra. The results will provide a critical update on the company's transition from a clinical-stage biotech to a potential commercial powerhouse in the immunology and hematology sectors.
